Biohaven (BHVN) Proxy Filing summary

Executive summary

• Advanced key programs in immunology, neurology, and oncology, focusing on extracellular protein degradation and precision therapies, with pivotal studies and data readouts expected in 2026.

• Maintained financial discipline through portfolio optimization, cost management, and strategic capital raising to support late-stage programs.

• Reinforced commitment to innovation with a robust discovery pipeline and ongoing evaluation of strategic partnerships in oncology.

Voting matters and shareholder proposals

• Shareholders will vote to elect three directors for terms expiring at the 2029 annual meeting.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026.

• Advisory vote on executive compensation (Say-on-Pay).

• Board recommends voting “FOR” all proposals.

Board of directors and corporate governance

• Board consists of eight members, with a majority classified as independent under NYSE rules.

• Board leadership structure separates Chair (CEO) and Lead Independent Director roles to enhance oversight.

• Annual board and committee evaluations are conducted to assess effectiveness.

• Three standing committees: audit, compensation, and nominating/corporate governance, all composed of independent directors.

• Equity ownership policy requires significant shareholding by directors and executives.